Athersys (NASDAQ:ATHX) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX) in a report released on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The company has a market cap of $833,000.00, a PE ratio of -0.01 and a beta of -0.90. Athersys has a 52-week low of $0.01 and a 52-week high of $1.99.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.